Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 4Active not recruiting 3Unknown 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 26Gastrointestinal 4Other solid neoplasm 1

Conditions

HER2+ Advanced Breast Cancer 1

Interventions

Injections 9Interviews as Topic 4Cisplatin 4Carboplatin 4toripalimab 3fludarabine 3envafolimab 3Pemetrexed 3Iodine-125 3Immune Checkpoint Inhibitors 3Fluorodeoxyglucose F18 3tislelizumab 2pembrolizumab 2Paclitaxel 2Oxaliplatin 2Drug Therapy 2Cyclophosphamide 2Cryosurgery 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1spartalizumab 1somatostatin receptor 2 1regorafenib 1olaparib 1nabiximols 1malic acid 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Trastuzumab × Other solid neoplasm × Clear all
NCT06027983 2025-09-23

Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors

National University Hospital, Singapore

Phase 1/2 Not yet recruiting
36 enrolled
BreastOther solid neoplasm

HER2+ Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡